DiaGenic signs agreement with Ferrer inCode

DiaGenic signs agreement with Ferrer inCode

DiaGenic signs agreement with Ferrer inCode for distribution of ADtect®
in Spain, Germany, Belgium, the Netherlands, Luxemburg, France, Italy,
and Portugal.

DiaGenic announces that it has signed an agreement for exclusive
distribution of ADtect® in major European countries with Ferrer inCode,
a biotech subsidiary of Grupo Ferrer Internacional. ADtect® uniquely
uses peripheral blood as the sample material to provide early
non-invasive diagnosis of Alzheimer's disease.

"Early detection enables subsequent early initiation of active
management strategies which may preserve the patients' level of function
for longer and increases the chances of delaying the progression of the
disease", said DiaGenic CEO Erik Christensen, M.D., Ph.D. "Current
evidence suggests that pharmacological treatments and caregiver
interventions can delay entry into nursing homes, thus reducing
healthcare costs. However, these cost savings are not being realized
because many patients with Alzheimer's disease are either not diagnosed
or diagnosed at a late stage of the disease. We envisage ADtect® with
its rapid and convenient sample collection playing a front line role."

"As front runners in the field of personalized medicine, we are
delighted to offer ADtect® to professionals and patients in our core
markets. The field of CNS is fast moving and we will continue to see
important developments within treatment and medical care of Alzheimer
patients. Therefore we strongly believe in an easy to use and
non-invasive test such as ADtect® which can provide early detection of
Alzheimer's disease and thereby improve quality of life", said Alfredo
Gracia M.D., Ph.D, Ferrer inCode's Chief Scientific Officer.

Following this latest distribution agreement, for the period from year
2010 up to and including year 2013 cumulative minimum volumes ADtect® in
17 European countries total approximately 85,000 tests.

Please find joint press release attached.

Contact person:
Erik Christensen, CEO
Telephone: + 47 95939918
E-mail: erik.christensen@diagenic.com

About DiaGenic ASA
DiaGenic is an innovative Norwegian biotechnology company that seeks to
create value for patients, partners, and investors by developing new and
more patient friendly methods for early detection of diseases. DiaGenic
is currently a world leader in analyzing gene expression signatures
related to disease in easily available clinical samples such as
peripheral blood. This unique method is based on the principle that even
when a disease is localized at a specific part of the body, secondary
responses, which are also characteristic of the disease, can be measured
in other parts. Significant potential in numerous diseases such as
breast cancer and Alzheimer's disease has been identified. The company
has been granted patents in the U.S. and Europe. DiaGenic is listed on
the Oslo Stock Exchange. For more information visit www.diagenic.com

About Ferrer inCode and Grupo Ferrer Internacional
Ferrer inCode is the biotech subsidiary of Grupo Ferrer Internacional,
working specifically in the field of personalized medicine as a provider
of diagnostic orientation, prognosis and prediction services based
chiefly on genomics, proteomics, metabolomics and bioinformatics. The
vision of Ferrer inCode is to help doctors make the most accurate
clinical decisions for every patient through advanced biotechnological
services. Grupo Ferrer Internacional is a privately held European
R&D-based pharmaco-chemical and medical device company headquartered in
Barcelona, Spain. Ferrer operates today in over 60 countries with the
overall aim of improving people's health and quality of life. Based on
its policy of continuous expansion throughout the world, Ferrer has
established strong industrial and commercial operations in Europe and
has extensive commercial experience in Latin America, Africa, the Middle
East and Far East. For more information on Ferrer,visit
www.ferrergrupo.com or www.ferrerincode.com.